Related Experiment Video
Updated: Apr 6, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Benefits of less frequent injections in advanced prostate cancer
1BPharm PhD, Zitro Consulting Services, Artarmon, NSW; and Conjoint Associate Professor, St Vincent's Clinical School, University of New South Wales, Darlinghurst, NSW.
Abstract:
Leuprorelin is indicated for the palliative treatment of advanced prostate cancer (APC) and is available as 1, 3, 4 and 6-monthly injections. There are advantages of longer leuprorelin injection intervals in the treatment of APC. Across all injection intervals, efficacy is similar and the majority of patients achieve testosterone suppression and normalisation of prostate-specific antigent. Treatment is well tolerated. Six-monthly leuprorelin injections are less costly to the healthcare system than the shorter interval injections.
More Related Videos
05:35Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
Published on: June 6, 2025
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Treatment Resistent Cancers